These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 30798007)
21. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. Schmidt J; Stürzebecher S; Toyka KV; Gold R J Neurosci Res; 2001 Jul; 65(1):59-67. PubMed ID: 11433430 [TBL] [Abstract][Full Text] [Related]
22. IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis. Cheng W; Zhao Q; Xi Y; Li C; Xu Y; Wang L; Niu X; Wang Z; Chen G Mol Immunol; 2015 Mar; 64(1):152-62. PubMed ID: 25433436 [TBL] [Abstract][Full Text] [Related]
23. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386 [TBL] [Abstract][Full Text] [Related]
24. Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis. Khorooshi R; Mørch MT; Holm TH; Berg CT; Dieu RT; Dræby D; Issazadeh-Navikas S; Weiss S; Lienenklaus S; Owens T Acta Neuropathol; 2015 Jul; 130(1):107-18. PubMed ID: 25869642 [TBL] [Abstract][Full Text] [Related]
26. Myeloid-derived suppressor cells prevent disruption of the gut barrier, preserve microbiota composition, and potentiate immunoregulatory pathways in a rat model of experimental autoimmune encephalomyelitis. Radojević D; Bekić M; Gruden-Movsesijan A; Ilić N; Dinić M; Bisenić A; Golić N; Vučević D; Đokić J; Tomić S Gut Microbes; 2022; 14(1):2127455. PubMed ID: 36184742 [TBL] [Abstract][Full Text] [Related]
27. Methylprednisolone alleviates multiple sclerosis by expanding myeloid-derived suppressor cells via glucocorticoid receptor β and S100A8/9 up-regulation. Wang Z; Zheng G; Li G; Wang M; Ma Z; Li H; Wang XY; Yi H J Cell Mol Med; 2020 Dec; 24(23):13703-13714. PubMed ID: 33094923 [TBL] [Abstract][Full Text] [Related]
29. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. van der Meide PH; de Labie MC; Ruuls SR; Groenestein RJ; Botman CA; Olsson T; Dijkstra CD J Neuroimmunol; 1998 Apr; 84(1):14-23. PubMed ID: 9600704 [TBL] [Abstract][Full Text] [Related]
30. IFN-β treatment requires B cells for efficacy in neuroautoimmunity. Schubert RD; Hu Y; Kumar G; Szeto S; Abraham P; Winderl J; Guthridge JM; Pardo G; Dunn J; Steinman L; Axtell RC J Immunol; 2015 Mar; 194(5):2110-6. PubMed ID: 25646307 [TBL] [Abstract][Full Text] [Related]
31. The effect of immunosuppressive drug cyclosporine A on myeloid-derived suppressor cells in transplanted mice. Han C; Wu T; Na N; Zhao Y; Li W; Zhao Y Inflamm Res; 2016 Sep; 65(9):679-88. PubMed ID: 27147271 [TBL] [Abstract][Full Text] [Related]
32. B cell function impacts the efficacy of IFN-β therapy in EAE. Agasing AM; Gawde S; Kumar G; Turner E; Axtell RC J Neuroimmunol; 2020 Jan; 338():577106. PubMed ID: 31715458 [TBL] [Abstract][Full Text] [Related]
33. The conundrum of interferon-β non-responsiveness in relapsing-remitting multiple sclerosis. Huber AK; Duncker PC; Irani DN Cytokine; 2015 Aug; 74(2):228-36. PubMed ID: 25691330 [TBL] [Abstract][Full Text] [Related]
34. Identification of new therapeutic targets for prevention of CNS inflammation. Owens T Expert Opin Ther Targets; 2002 Apr; 6(2):203-15. PubMed ID: 12223081 [TBL] [Abstract][Full Text] [Related]
35. Amelioration of Experimental Autoimmune Encephalomyelitis in Mice by Interferon-Beta Gene Therapy, Using a Long-Term Expression Plasmid Vector. Hamana A; Takahashi Y; Tanioka A; Nishikawa M; Takakura Y Mol Pharm; 2017 Apr; 14(4):1212-1217. PubMed ID: 28257578 [TBL] [Abstract][Full Text] [Related]
36. Sema4A inhibits the therapeutic effect of IFN-β in EAE. Koda T; Okuno T; Takata K; Honorat JA; Kinoshita M; Tada S; Moriya M; Sakoda S; Mochizuki H; Kumanogoh A; Nakatsuji Y J Neuroimmunol; 2014 Mar; 268(1-2):43-9. PubMed ID: 24439904 [TBL] [Abstract][Full Text] [Related]
37. Protective Effects on Central Nervous System by Acidic Polysaccharide of Panax ginseng in Relapse-Remitting Experimental Autoimmune Encephalomyelitis-Induced SJL/J Mice. Bing SJ; Ha D; Hwang I; Park E; Ahn G; Song JY; Jee Y Am J Chin Med; 2016; 44(6):1099-1110. PubMed ID: 27627913 [TBL] [Abstract][Full Text] [Related]
38. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review. Aharoni R J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599 [TBL] [Abstract][Full Text] [Related]
39. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971 [TBL] [Abstract][Full Text] [Related]